$XTLB News

XTL Receives Nasdaq Noncompliance Letter

XTL Biopharmaceuticals Signs Agreement To Acquire Psyga Bio; Financial Terms Undisclosed

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

XTL Biopharma To Implement 1-For-4 Reverse ADS Split, Effective March 25, 2026

XTL Biopharmaceuticals Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

XTL Biopharmaceuticals Moves To Acquire 85% Of NeuroNOS And Has Already Scheduled A Shareholders Meeting For February 17, 2026 To Approve A Private Placement Of Up To $2M

XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency

XTL Biopharmaceuticals Receives Nasdaq Noncompliance Notice, Gets Time Through March 6 To Regain Compliance

XTL Biopharmaceuticals shares are trading higher after the company announced a binding agreement to acquire 85% of NeuroNOS.

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

XTL Biopharmaceuticals Receives Nasdaq Notification Letter

XTL Biopharmaceuticals CFO Itay Weinstein Resigns; Niv Segal Appointed Successor, Effective December 11, 2025

XTL Names Mr. Noam Band as its New Chief Executive Officer

XTL Biopharmaceuticals Announces The Appointment Of Noam Band As The Company's New CEO; Shlomo Shalev Will Continue As The Chairman Of The Board Of Directors

X T L Biopharmaceuticals Earlier Announced Definitive Exclusive Sublicense Agreement With Biossil

XTL Biopharmaceuticals Faces Financial Dispute After Acquisition

XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million

XTL Biopharmaceuticals Expands with AI Company Acquisition

XTL Biopharmaceuticals completes acquisition of The Social Proxy